Drug delivery

Dr Jason Bellia, Senior Patent Examiner at the UK Intellectual Property Office (IPO) I will look at just two of a vast number of routes - one to deliver nucleic acids across cell membranes and another looking...

The SPC manufacturing waiver: curtailing protection or boosting competition?

Lucy O’Brien, Trainee Patent Attorney, A. A. Thornton & Co. Supplementary Protection Certificates (SPCs) are a valuable IP asset to most major life science businesses. The ability to extend the term of a patent relating to a...

Plant patentability and the European Patent Office – what is the latest update?

Plant patentability has long been a contentious issue throughout intellectual property and scientific circles. The question as to whether plants or animals created through essentially biological processes, such as genetic or selective breeding, can be...

Are your innovations protected?

Innovation is something that defines the biosciences sector. The UK biotechnology and medical industries are among some of the most progressive in the world with billions invested annually on creating industry-leading drugs, techniques, therapies, and...

Compulsory licensing of pharmaceuticals: A solution to high drug prices?

The UK continues to grapple with its departure – or not – from the European Union, and whilst the outcome remains unclear, one thing now seems certain: before long there will be a general...

Considering a pharma and bioscience patent? The UK Intellectual Property Office maps out the...

Lawrence Cullen & Laura Starrs, Patent Examining Group Heads, IPO Managing a patent portfolio requires, among many skills, the ability to anticipate the future. This is especially true in the fields of bioscience and pharma where,...

The importance of Intellectual Property strategy; creating a foundation on which to build value...

Dr Emma Longland and Craig Thomson of HGF writing for the Chartered Institute of Patent Attorneys Most companies in the Biotech space appreciate the need for patent protection; after all, no company wants to bring...

How intellectual property can help 3D printing support, not harm, medtech

3D printing, or additive manufacturing, is frequently, and rightly, hailed as the next revolution in technology. Since its inception in 1986, 3D printing has transformed numerous sectors including aviation, manufacturing, and energy, and altered perceptions...

Access to Intellectual Property (IP) Rights in a Time of Emergency – Patent Pools...

Alex Bone, Patent Attorney, Partner,  AA Thornton The pharmaceutical and healthcare industry is often accused of misusing IP to extend exclusivity and delay reasonably priced access to life saving technologies. The recent pandemic has focussed attention...

Patenting aerospace medicines – the final frontier?

Research and development (R&D) into aerospace medicine can be viewed as falling into one of two camps: that aimed at adapting an existing ‘terrestrial’ medicine for use in the aerospace environment; and that which...

UK Supreme Court inflicts more patent pain on Warner-Lambert

Eilidh Pugh, Pharmaceutical Patent Attorney, AdamsonJones. The UK Supreme Court has handed down its much-anticipated decision in WarnerLambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis. The case is important because it is the...

Preparations for AI patenting in Europe

The current era of rapid technological development requires industry to be quick to respond to challenges and opportunities, with many choosing to exploit new AI technologies rather than wait to be disrupted by competitors. Intellectual...

Biosimilars and Patents

Leonita Paulraj - Associate, AA Thornton The majority of the world’s biggest selling medicines can be classified as “biologics” or “biopharmaceuticals”. Such medicines contain one or more biologically active product produced from (or containing components of)...

How to protect your IP rights in Europe

Intellectual property rights are territorial rights, meaning that the protection afforded by a granted patent or a registered trademark is geographically limited. Many companies that protect their inventions, brands or product designs in their home...

Shanks v Unilever – An opening of the claim floodgates?

Varuni Paranavitane, IP Solicitor,  AA Thornton At the end of last year Professor Shanks was awarded £2 million for an invention relating to a glucose sensor made while employed working for Unilever.  What does this mean...

The IP journey and risk mitigation

Paul Storer Senior Policy Adviser in the Business Support Policy Team at the IPO Resolving IP disputes can be costly and the Intellectual Property Office continues to seek to reduce costs for businesses, not only in...